No enrollment history yet? How a new site wins its first trial — and gets shortlisted anyway

The catch-22 is real — and it is not the whole screen

Sponsors screen on history because history is easy to score. Past enrollment, retention, and audit results are tidy numbers. A new site has none of them, so it is often filtered out before a human being reads anything about it.

But history is a proxy, not the thing itself. A sponsor wants to know whether your patients exist, whether your team will follow the protocol, whether your data will be clean, and whether you will answer quickly when something goes wrong. All of that can be answered before your first interventional trial — in writing, in advance. Stop presenting yourself as a site waiting for a chance. Present yourself as one that has built the systems a trial needs, and is matching them to the right first study.

Start where history is not the entry fee

Registry and observational studies are the most practical first step. Patients are observed and their data recorded, but no experimental treatment is assigned, so the risk and operational burden are lower — and sponsors are often more willing to work with a site still building its record.

Treat a registry as seriously as a pivotal trial. Hit data-entry deadlines, keep source documents orderly, and close queries fast. Record your performance as you go: patients identified, consented, and completed, and how quickly you resolved data questions.

At the end, you can say you completed a study, on time, with documented numbers. That is a track record, even if a modest one, and it trains your team in consenting, documentation, and follow-up — exactly what selectors worry a new site lacks. Chart reviews help the same way: collect evidence of execution wherever it is offered.

Build a one-page capability snapshot sponsors can trust

A selector may give your site ninety seconds. A one-page capability snapshot makes those seconds count. Keep every claim verifiable, and update it whenever something changes:

• Facilities: examination rooms, procedure space, secure drug and sample storage, monitored refrigeration, and emergency equipment, stated plainly.
• Equipment: the specific devices you own or can access, with calibration practices noted, not a generic promise that equipment is available.
• Team: the principal investigator (PI), sub-investigators, coordinators, and support staff, with licenses, certifications, and clinical experience for each person.
• Training: current Good Clinical Practice (GCP) training for every team member who will touch the study, with dates you can produce on request.
• Systems: your standard operating procedure (SOP) library, listed by title, covering consent, delegation, training, safety reporting, and data handling.
• Patient population: counts from your own practice records, by condition and age range, with date range and counting method stated.
• Quality record: where it applies, say it clearly. At Amavita Research Services, we state our population of more than 18,000 active cardiology patients and our record of zero Food and Drug Administration (FDA) Form 483 findings. Form 483 is the form FDA inspectors use to record observations after an inspection. With no inspection history yet, say what quality checks you have built instead.

Treat the feasibility questionnaire as your first audition

Long before a sponsor sees your site, it sees your feasibility questionnaire. That document is an audition, scored on speed, accuracy, and consistency.

Answer fast. A complete, honest response in two days tells a selector more than a polished response in three weeks. Acknowledge requests the same business day, and complete them within a deadline you choose and keep.

Answer accurately. Pull patient counts from your records, not memory or optimism. Run the actual search and report the actual result, even when it is smaller than you wish it were.

Answer consistently. Your questionnaire, capability snapshot, and selection conversation must tell the same story. Discrepancies read as carelessness — the one trait no sponsor will risk in a new site.

Finally, add one paragraph most new sites omit: how you will find and keep patients. Name your referral sources, your recall process, and who owns recruitment week by week. A plan with an owner beats enthusiasm.

Be precise about what you cannot do

New sites often say yes to everything, fearing a single no will end the conversation. Experienced selectors hear the opposite: a site that claims every procedure, schedule, and population is a site that has not read the protocol carefully.

State your limits alongside your strengths. If a protocol requires an overnight stay you cannot provide, say so — and what you could provide instead. If a visit window conflicts with your staffing, raise it during feasibility, not after activation. If equipment must be leased, name that step and its timeline.

Precision builds trust because it is costly to fake. Sponsors remember the honest site when the next, better-fitting study arrives — and that memory is often how a first shortlist actually happens.

Let the principal investigator carry weight — responsibly

When a site has no history, the principal investigator's clinical reputation becomes part of the evidence. Describe the principal investigator's years in practice, specialty focus, and hospital and referral relationships. A well-regarded clinician who refers and is referred to is a recruitment asset, and selectors know it.

Keep the claims clinical and checkable. Board certification, licensure, practice history, and a curriculum vitae a sponsor can review are evidence. Adjectives are not. Make sure the principal investigator is visibly engaged in selection conversations, too: one who joins the call, knows the protocol, and asks sharp questions signals that oversight will be real, not nominal. Under GCP, that oversight is the principal investigator's personal responsibility, so demonstrating it early answers a regulatory concern and a commercial one.

Target the patients you already see

The fastest route to a first trial is a study whose eligibility criteria match the patients already in your waiting room. Do not chase prestigious studies requiring populations you would have to build from nothing. Review your practice data, identify the conditions you see in volume, and pursue studies in those conditions.

This alignment makes your feasibility numbers honest, because they come from real records, and your recruitment plan credible, because the patients already trust your team. It also makes strong first enrollment far more likely — what turns a first trial into a second one. Tell CROs and sponsors plainly which patient groups you serve well. A narrow, true match beats a broad, hopeful pitch.

A thirty-day starter checklist

Complete these steps within thirty days:

1. Pull defensible patient counts from your own records, by condition, with the method and date range written down.
2. Draft your one-page capability snapshot and verify every claim on it.
3. Confirm current GCP training for the principal investigator and every team member, and file the certificates for quick production.
4. List your standard operating procedures by title and close any gap on consent, delegation, safety reporting, or data handling.
5. Set a feasibility turnaround deadline, and assign one owner for every questionnaire.
6. Apply for one registry or observational study that fits your existing patient population.
7. Prepare a short recruitment plan naming your referral sources and the team member who owns recruitment.

The shortlist is earned before enrollment begins

No enrollment history is a gap, not a verdict. Sponsors shortlist new sites when the evidence — documented registry performance, a verifiable capability snapshot, a fast and honest feasibility response, stated limits, an engaged principal investigator, and a study matched to real patients — makes that absence feel like a small risk instead of an unknown one. Build it now, and your first trial stops being a favor. It becomes the logical next step your site has prepared for.